Oxa-azaspiro derivatives: A novel class of triple re-uptake inhibitors

ChemMedChem

Volumn 5, Issue 3, 2010, Pages 361-366

  Bettati, Michela ^a   Cavanni, Paolo ^a   Di Fabio, Romano ^a   Oliosi, Beatrice ^a   Perini, Ornella ^a   Scheid, Gunther ^a   Tedesco, Giovanna ^a   Zonzini, Laura ^a   Micheli, Fabrizio ^a  

^a GSK   (Italy)

Author keywords

Dopamine; Inhibitors; Noradrenaline; Serotonin

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 10 (3,4 DICHLOROPHENYL) 2 OXA 7 AZASPIRO[4.5]DECANE; 11 (3,4 DICHLOROPHENYL) 2 OXA 8 AZASPIRO[5.5]UNDECANE; 4 (3,4 DICHLOROPHENYL)OCTAHYDRO 2H PYRANO[4,3 B]PYRIDINE; 9 (3,4 DICHLOROPHENYL) 2 OXA 6 AZASPIRO[3.5]NONANE; ANTIDEPRESSANT AGENT; CYTOCHROME P450; DOPAMINE TRANSPORTER; ELECTROPHILE; FORMALDEHYDE; INDATRALINE; NORADRENALIN TRANSPORTER; OXAAZASPIRO DERIVATIVE; SEROTONIN TRANSPORTER; SPIRO COMPOUND; TETRAHYDROFURAN DERIVATIVE; TETRAHYDROPYRAN DERIVATIVE; UNCLASSIFIED DRUG;

AMINE TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; COMPUTER MODEL; CONTROLLED STUDY; CYCLIZATION; DEPROTECTION REACTION; DRUG BINDING; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; LIVER MICROSOME; MALE; MITSUNOBU REACTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OZONOLYSIS; PHARMACOPHORE; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; REDUCTION; STEREOCHEMISTRY; VALIDATION STUDY;

AZA COMPOUNDS; CELL LINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MOLECULAR STRUCTURE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SPIRO COMPOUNDS;

EID: 77249095151     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900482     Document Type: Article

References (21)

1. a) S. K. Kulkarni, A. Dhir, Expert Opin. Invest. Drugs 2009, 18, 767;
2. b) M. L. Wong, J. Licinio, Nat. Rev. Drug Discovery 2004, 3, 136;
3. c) M. J. Millan, Eur. J. Pharmacol. 2004, 500, 371;
4. d) C. B. Nemeroff, J. Psychiatr. Res. 2007, 41, 189.
5. a) J. Arnt, A. V. Christensen, J. Hyttel, Naunyn-Schmiedeberg's Arch. Pharmacol. 1985, 329, 101;
6. b) Z. Chen, P. Skolnick, Expert Opin. Invest. Drugs 2007, 16, 1365.
7. a) J. Scheel-Krüger, P. Moldt, F. Ẅtjen, (Neurosearch, Ballerup, Denmark), WO/1997/30997, 1997;
8. b) J. Scheel-Kr̈ger, G. Olsen, E. Nielsen, B. H. Dahl, L. H. Jensen, (Neurosearch, Ballerup, Denmark), WO/1997/ 16451, 1997.
9. Maestro version 8.5.111 (Schrodinger LLC).
10. BatchMin version 9.6 (Schrodinger LLC).
11. Phase version 3.0.110 (Schrodinger LLC).
12. a) D. Crowe, D. A. Jones, (Smithkline-Beecham plc, Brentford, UK), WO/ 2001/014335, 2001;
13. b) L. De Ferra, P. Massardo, O. Piccolo, G. Cignarella, (Chemi SpA, Milan, Italy), EP1074550, 2000.
14. K. C. Swamy, N. N. Kumara, E. Balaraman, K. V. Kumar, Chem. Rev. 2009, 109, 2551.
15. A. R. Olofson, Pure Appl. Chem. 1988, 60, 1715.
16. a) S. P. H. Mee, V. Lee, J. E. Baldwin, Angew. Chem. 2004, 116, 1152;
17. Angew. Chem. Int. Ed. 2004, 43, 1132;
18. b) J. K. Stille, Angew. Chem. 1986, 98, 504;
19. Angew. Chem. Int. Ed. Engl. 1986, 25, 508;
20. c) M. Vinicius Nora De Souza, Curr. Org. Synth. 2006, 3, 313.
21. Y. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099.